ImmunityBio (IBRX) Asset Writedowns and Impairment (2014 - 2023)

ImmunityBio (IBRX) has 4 years of Asset Writedowns and Impairment data on file, last reported at $886000.0 in Q4 2023.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $886000.0 in Q4 2023; TTM through Dec 2023 was -$9.8 million, a N/A change from a year earlier, with the FY2023 full-year figure at $886000.0, up 30.1% from the prior year.
• Asset Writedowns and Impairment for Q4 2023 stood at $886000.0, up from -$10.7 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for IBRX reached as high as $10.7 million in Q3 2020 and fell as low as -$10.7 million in Q4 2020.
• Historically, Asset Writedowns and Impairment has averaged $402500.0 across 3 years, with a median of $805000.0 in 2019.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 1572.38% in 2020 and fell as far as 1572.38% in 2020.
• Year by year, Asset Writedowns and Impairment stood at $724000.0 in 2019, then slumped by 1572.38% to -$10.7 million in 2020, then soared by 108.31% to $886000.0 in 2023.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $886000.0 in Q4 2023, -$10.7 million in Q4 2020, and $10.7 million in Q3 2020.